Profile data is unavailable for this security.
About the company
Wockhardt Limited is a research-based global pharmaceutical and biotech company. The Company is engaged in the pharmaceutical business. It focuses on the unmet need for antibacterial drugs that are effective against the menace of untreatable superbugs. It manufactures and supplies branded and generic finished formulations, as well as intermediate products like active pharmaceutical ingredients (APIs), worldwide. The Company’s products in India include EMROK, MERIWOK, REINVEXIN, ERLISO, METHYCOBAL TABLET, METHYCOBAL INJ, METHYCOBAL D, HAPID, PROXYFEN NANO GEL, LIVATIRA TABLET, LIVATIRA INJ, GABAWOK NT 100, GABAWOK NT 400, ETOBRIX 90, ETOBRIX TH4, ETOBRIX P, GLARZEN CARTRIDGE, GLARZEN DISPOPEN 2, ESOWOK D, TERITIDE, GLIMADAY, SITAWOK, GLARITUS, TRIMETADAY, MOPADAY, INOGLA, and ZINODAP. The Company has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.
- Revenue in INR (TTM)28.93bn
- Net income in INR-3.43bn
- Incorporated1999
- Employees2.39k
- LocationWockhardt LtdWockhardt TowersBandra Kurla Complex, Bandra (East)MUMBAI 400051IndiaIND
- Phone+91 2 226534444
- Fax+91 2 226523905
- Websitehttp://www.wockhardt.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| F D C Ltd | 20.45bn | 3.14bn | 87.30bn | 6.66k | 27.91 | -- | 24.55 | 4.27 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Blue Jet Healthcare Ltd | 6.95bn | 1.57bn | 90.75bn | 447.00 | 57.64 | -- | 49.61 | 13.06 | 9.08 | 9.08 | 40.07 | -- | -- | -- | -- | 15,547,110.00 | -- | -- | -- | -- | 55.54 | -- | 22.65 | -- | -- | 124.37 | -- | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.01bn | 2.31bn | 112.90bn | -- | 48.94 | 61.16 | 48.18 | 14.10 | 100.17 | 100.17 | 347.67 | 80.15 | -- | -- | -- | -- | -- | -- | -- | -- | 71.64 | -- | 28.81 | -- | 2.27 | 3,260.00 | 0.0986 | -- | -- | -- | -- | -- | -- | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 131.03bn | 2.00k | 39.22 | -- | 31.61 | 5.78 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 134.90bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Strides Pharma Science Ltd | 42.09bn | -475.19m | 143.40bn | 3.07k | -- | -- | 103.81 | 3.41 | -5.44 | 0.4871 | 460.14 | -- | -- | -- | -- | 13,731,270.00 | -- | -1.68 | -- | -2.97 | 60.18 | 51.39 | -1.68 | -3.36 | -- | 1.24 | -- | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Glenmark Life Sciences Ltd | 22.93bn | 4.47bn | 144.34bn | 2.01k | 32.36 | -- | 28.75 | 6.29 | 36.41 | 36.41 | 186.81 | -- | -- | -- | -- | 11,387,190.00 | -- | 18.28 | -- | 29.99 | 54.58 | 53.40 | 19.49 | 20.23 | -- | 389.45 | -- | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Caplin Point Laboratories Ltd | 17.58bn | 4.78bn | 144.91bn | 859.00 | 30.42 | -- | 26.83 | 8.24 | 62.67 | 62.67 | 230.62 | -- | -- | -- | -- | 20,462,630.00 | -- | 19.83 | -- | 22.82 | 58.41 | 53.38 | 27.43 | 25.39 | -- | 1,525.59 | -- | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Granules India Ltd | 47.01bn | 4.92bn | 146.35bn | 4.12k | 29.76 | -- | 20.82 | 3.11 | 20.29 | 20.29 | 193.87 | -- | -- | -- | -- | 11,403,970.00 | -- | 10.68 | -- | 16.18 | 56.89 | 48.83 | 10.47 | 11.82 | -- | 6.95 | -- | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Wockhardt Ltd | 28.93bn | -3.43bn | 152.91bn | 2.39k | -- | -- | -- | 5.29 | -23.75 | -23.75 | 199.60 | -- | -- | -- | -- | 12,084,380.00 | -- | -4.56 | -- | -8.29 | 58.66 | 55.26 | -12.17 | -12.70 | -- | 0.0764 | -- | -- | 5.55 | -4.73 | 17.17 | -- | -4.71 | -- |
| Sanofi India Ltd | 23.83bn | 4.30bn | 159.26bn | 2.17k | 37.06 | 23.26 | 34.03 | 6.68 | 186.62 | 229.86 | 1,034.61 | 297.26 | 1.67 | 2.73 | 15.60 | 10,960,440.00 | 30.08 | 22.42 | 57.55 | 30.21 | 55.95 | 55.52 | 18.04 | 21.03 | 0.8140 | 435.86 | 0.0313 | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Jubilant Pharmova Ltd | 68.48bn | 5.53bn | 181.53bn | 995.00 | 32.88 | -- | 19.49 | 2.65 | 34.86 | 34.86 | 432.21 | -- | -- | -- | -- | 68,821,100.00 | -- | 2.96 | -- | 3.55 | 68.13 | 68.47 | 8.01 | 5.13 | -- | 2.34 | -- | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Neuland Laboratories Ltd. | 16.35bn | 3.36bn | 182.80bn | 1.65k | 54.39 | -- | 45.87 | 11.18 | 261.94 | 261.94 | 1,274.50 | -- | -- | -- | -- | 9,922,259.00 | -- | 9.25 | -- | 12.71 | 53.32 | 47.81 | 20.55 | 11.99 | -- | 29.52 | -- | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Eris Lifesciences Ltd | 22.62bn | 3.80bn | 188.70bn | 3.08k | 49.67 | -- | 30.91 | 8.34 | 27.91 | 27.91 | 166.06 | -- | -- | -- | -- | 7,344,939.00 | -- | 13.42 | -- | 16.80 | 78.68 | 79.98 | 17.36 | 24.96 | -- | 4.20 | -- | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 194.73bn | 940.00 | 203.14 | -- | 175.57 | 14.03 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 198.32bn | 1.38k | 63.34 | -- | 54.05 | 19.11 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
Data as of Oct 11 2024. Currency figures normalised to Wockhardt Ltd's reporting currency: Indian Rupee INR
5.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.62m | 1.71% |
| ICICI Prudential Asset Management Co. Ltd.as of 31 Jul 2024 | 1.95m | 1.27% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 932.42k | 0.61% |
| Samco Asset Management Pvt. Ltd.as of 31 Jul 2024 | 811.27k | 0.53% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 601.34k | 0.39% |
| Invesco Asset Management (India) Pvt Ltd.as of 31 Jul 2024 | 564.13k | 0.37% |
| Mirae Asset Investment Managers (India) Pvt Ltd.as of 31 Jul 2024 | 483.56k | 0.32% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 351.08k | 0.23% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 275.63k | 0.18% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jul 2024 | 232.11k | 0.15% |
More ▼
Data from 31 Dec 2023 - 31 Jul 2024Source: FactSet Research Systems Inc.
